S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
NASDAQ:TNXP

Tonix Pharmaceuticals - TNXP Stock Forecast, Price & News

$0.39
+0.02 (+3.96%)
(As of 12/2/2022 09:01 PM ET)
Add
Compare
Today's Range
$0.36
▼
$0.41
50-Day Range
$0.38
▼
$0.57
52-Week Range
$0.36
▼
$14.36
Volume
2.77 million shs
Average Volume
4.06 million shs
Market Capitalization
$22.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.20

Tonix Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
4,773.1% Upside
$19.20 Price Target
Short Interest
Healthy
1.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.24mentions of Tonix Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.42) to ($1.60) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

427th out of 1,033 stocks

Pharmaceutical Preparations Industry

185th out of 502 stocks

See Top Rated MarketRank™ Stocks Here
TNXP stock logo

About Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company headquartered in Chatham, New Jersey. The company was founded in 2007 and then later went public in 2013. Tonix Pharmaceuticals is led by Seth Lederman who has been CEO since co-founding the company. Mr. Lederman was an Associate Professor at Columbia University for more than 2 decades before venturing into the private sector. Tonix Pharmaceuticals is his second venture, the first was bought out after developing an effective treatment for colorectal cancer. The company operates through three facilities located in Massachusetts, Maryland, and Montana.

The two east-coast facilities are the R&D center and the Advanced Development Center while manufacturing is located in Montana. The Maryland facility is rated BSL-2 with some areas rated BSL-3 which allows for the handling of live viruses. The Massachusetts facility is intended to enhance the company’s R&D and analytics capabilities as well as facilitate vaccine production at the clinical trial scale. The Montana facility will support Phase III trials as well as the mass production of approved treatments.

Tonix Pharmaceuticals focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering across a wide spectrum of ailments and treatments. Among them is COVID-19 for which the company has several products in development.

Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The types of diseases the company targets are widely occurring but hard to treat so breakthroughs of any kind could be significant sources of income. The company has several candidates in pre-clinical and clinical trials with two standouts that are on track for FDA approval. Resilient, a treatment for Fibromyalgia, and Prevail, a treatment for long-COVID, entered Phase III and Phase II trials in 2022.

The immunology portfolio includes treatments for organ transplant rejection, autoimmunity, and cancer, and several in this group have shown efficacy against multiple indications. The company’s infectious disease pipeline includes several promising treatments for viruses afflicting the world today. The TNX-80 vaccine is intended to prevent smallpox and monkeypox while TNX-1840 and TNX-1850 are live virus vaccines to fight COVID-19, as will TNX-3500 and TNX-102, which are small molecule antiviral drugs.

Tonix Pharmaceuticals CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction including Resilient, which is in mid-Phase 3 development for the management of fibromyalgia. Other products in the pipeline are TNX-1900 which is in development for the prevention of migraine headaches and TNX-1300 which is designed to treat cocaine intoxication.

Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TNXP Stock News Headlines

November 30, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress
November 27, 2022 | americanbankingnews.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by Analysts at StockNews.com
December 5, 2022 | Vantage Point (Ad)
Surprise Yourself, Predict the Trends with A.I.
Imagine a tool similar to Google...powered by A.I. – but to help you search, pick and predict stocks 1 - 3 days ahead with up to 87.4% proven accuracy. Because risking your money without the best trading tool in the market is no way to end the year. Count Me In for the Free Live A.I. Training . pixel
November 23, 2022 | finance.yahoo.com
Tonix Pharmaceuticals to Participate in the A.G.P. Biotech Conference
November 16, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society for Neuroscience
November 7, 2022 | msn.com
Recap: Tonix Pharmaceuticals Q3 Earnings
November 7, 2022 | seekingalpha.com
Tonix Pharmaceuticals GAAP EPS of -$0.69 beats by $0.33
October 25, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock
December 5, 2022 | Vantage Point (Ad)
Surprise Yourself, Predict the Trends with A.I.
Imagine a tool similar to Google...powered by A.I. – but to help you search, pick and predict stocks 1 - 3 days ahead with up to 87.4% proven accuracy. Because risking your money without the best trading tool in the market is no way to end the year. Count Me In for the Free Live A.I. Training . pixel
October 25, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock
October 17, 2022 | finance.yahoo.com
Tonix Pharmaceuticals to Participate in the 2022 BIO-Europe Conference
October 6, 2022 | proactiveinvestors.com
Tonix Pharmaceuticals says IND application for TNX-601 to treat depression is a major milestone
October 3, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder
September 22, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on Pain
September 15, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)
September 11, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Holding Corp. (TNXP)
August 23, 2022 | msn.com
Looking Into Tonix Pharmaceuticals's Recent Short Interest
August 22, 2022 | msn.com
Tonix Pharmaceuticals Commences Mid-Stage Long COVID Study, Sees Interim Report In H1 2023
August 11, 2022 | proactiveinvestors.com
Tonix Pharmaceuticals prepares to tackle monkeypox outbreak with TNX-801 vaccine
August 2, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication
August 1, 2022 | benzinga.com
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain
July 28, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection
July 25, 2022 | finance.yahoo.com
Siga, Peers Rise on Optimism Over Monkeypox Therapies
July 11, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder
July 6, 2022 | finance.yahoo.com
Tonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USA
June 24, 2022 | finance.yahoo.com
New to The Street TV / Newsmax TV Announces its Six Interviews for This Week's TV Broadcast, Episode #358, June 26, 2022, 10-11 AM ET
June 21, 2022 | seekingalpha.com
Is Tonix Pharma's Stock A Buy Or Sell After Buyback Plan Announcement?
See More Headlines
Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TNXP Company Calendar

Last Earnings
11/07/2021
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/13/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNXP
CUSIP
N/A
CIK
1430306
Web
www.tonixpharma.com
Phone
(212) 980-9155
Fax
212-923-5700
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.20
High Stock Price Forecast
$19.20
Low Stock Price Forecast
$19.20
Forecasted Upside/Downside
+4,773.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($5.7438)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-92,290,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-48.92%
Return on Assets
-43.97%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.33
Quick Ratio
11.33

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$14.08 per share
Price / Book
0.03

Miscellaneous

Outstanding Shares
57,536,000
Free Float
56,385,000
Market Cap
$22.67 million
Optionable
Optionable
Beta
1.61

Key Executives

  • Dr. Seth Lederman M.D.Dr. Seth Lederman M.D. (Age 64)
    Co-Founder, Pres, CEO & Chairman
    Comp: $1.18M
  • Mr. Bradley Saenger CPA (Age 48)
    CPA, CFO & Treasurer
    Comp: $595k
  • Dr. Gregory M. Sullivan M.D. (Age 56)
    Chief Medical Officer & Sec.
    Comp: $616k
  • Mrs. Jessica Edgar Morris
    Chief Operating Officer
  • Dr. Herbert W. Harris M.D.
    Ph.D., Exec. VP of Translational Medicine
  • Dr. Bruce L. Daugherty M.B.A. (Age 64)
    Ph.D., Exec. VP of Research
  • Ms. Siobhan Fogarty B.Sc.
    M.Sc., Exec. VP of Product Devel.
  • Dr. Darryl Rideout Ph.D.
    Exec. VP of Experimental Chemistry
  • Dr. Sina Bavari Ph.D.
    Exec. VP of Infectious Disease R&D
  • Dr. Daniel J. Clauw M.D.
    Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TNXP Stock - Frequently Asked Questions

Should I buy or sell Tonix Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNXP shares.
View TNXP analyst ratings or view top-rated stocks.

What is Tonix Pharmaceuticals' stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month price targets for Tonix Pharmaceuticals' shares. Their TNXP share price forecasts range from $19.20 to $19.20. On average, they anticipate the company's stock price to reach $19.20 in the next year. This suggests a possible upside of 4,773.1% from the stock's current price.
View analysts price targets for TNXP or view top-rated stocks among Wall Street analysts.

How have TNXP shares performed in 2022?

Tonix Pharmaceuticals' stock was trading at $11.4464 on January 1st, 2022. Since then, TNXP stock has decreased by 96.6% and is now trading at $0.3940.
View the best growth stocks for 2022 here.

Are investors shorting Tonix Pharmaceuticals?

Tonix Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 618,200 shares, a decrease of 34.6% from the October 31st total of 945,400 shares. Based on an average daily volume of 2,000,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.1% of the shares of the company are sold short.
View Tonix Pharmaceuticals' Short Interest.

When is Tonix Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our TNXP earnings forecast.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced its quarterly earnings data on Sunday, November, 7th. The company reported ($1.60) earnings per share for the quarter, topping analysts' consensus estimates of ($2.24) by $0.64.

When did Tonix Pharmaceuticals' stock split?

Tonix Pharmaceuticals shares reverse split on Tuesday, May 17th 2022. The 1-32 reverse split was announced on Tuesday, May 17th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Who are Tonix Pharmaceuticals' major shareholders?

Tonix Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.27%), Vanguard Group Inc. (1.49%), BlackRock Inc. (0.54%), Two Sigma Investments LP (0.35%) and Virtu Financial LLC (0.29%). Insiders that own company stock include Daniel Wintner Goodman, Gregory M Sullivan, James Treco, Margaret Smith Bell and Seth Lederman.
View institutional ownership trends.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $0.39.

How much money does Tonix Pharmaceuticals make?

Tonix Pharmaceuticals (NASDAQ:TNXP) has a market capitalization of $22.67 million. The company earns $-92,290,000.00 in net income (profit) each year or ($5.7438) on an earnings per share basis.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The official website for the company is www.tonixpharma.com. The company can be reached via phone at (212) 980-9155, via email at investor.relations@tonixpharma.com, or via fax at 212-923-5700.

This page (NASDAQ:TNXP) was last updated on 12/5/2022 by MarketBeat.com Staff